Cumulative incidence of false-positive results in repeated, multimodal cancer screening
- PMID: 19433838
- PMCID: PMC2682972
- DOI: 10.1370/afm.942
Cumulative incidence of false-positive results in repeated, multimodal cancer screening
Abstract
Purpose: Multiple cancer screening tests have been advocated for the general population; however, clinicians and patients are not always well-informed of screening burdens. We sought to determine the cumulative risk of a false-positive screening result and the resulting risk of a diagnostic procedure for an individual participating in a multimodal cancer screening program.
Methods: Data were analyzed from the intervention arm of the ongoing Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, a randomized controlled trial to determine the effects of prostate, lung, colorectal, and ovarian cancer screening on disease-specific mortality. The 68,436 participants, aged 55 to 74 years, were randomized to screening or usual care. Women received serial serum tests to detect cancer antigen 125 (CA-125), transvaginal sonograms, posteroanterior-view chest radiographs, and flexible sigmoidoscopies. Men received serial chest radiographs, flexible sigmoidoscopies, digital rectal examinations, and serum prostate-specific antigen tests. Fourteen screening examinations for each sex were possible during the 3-year screening period.
Results: After 14 tests, the cumulative risk of having at least 1 false-positive screening test is 60.4% (95% CI, 59.8%-61.0%) for men, and 48.8% (95% CI, 48.1%-49.4%) for women. The cumulative risk after 14 tests of undergoing an invasive diagnostic procedure prompted by a false-positive test is 28.5% (CI, 27.8%-29.3%) for men and 22.1% (95% CI, 21.4%-22.7%) for women.
Conclusions: For an individual in a multimodal cancer screening trial, the risk of a false-positive finding is about 50% or greater by the 14th test. Physicians should educate patients about the likelihood of false positives and resulting diagnostic interventions when counseling about cancer screening.
Trial registration: ClinicalTrials.gov NCT00002540.
Figures
Similar articles
-
Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.Rev Recent Clin Trials. 2018;13(4):257-273. doi: 10.2174/1574887113666180409153059. Rev Recent Clin Trials. 2018. PMID: 29629665 Clinical Trial.
-
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S. doi: 10.1016/s0197-2456(00)00097-0. Control Clin Trials. 2000. PMID: 11189683
-
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6. J Natl Cancer Inst. 2012. PMID: 22228146 Free PMC article. Clinical Trial.
-
The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results.Rev Recent Clin Trials. 2015;10(3):173-80. doi: 10.2174/1574887110666150730123004. Rev Recent Clin Trials. 2015. PMID: 26238115 Review.
-
Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2018 Feb 13;319(6):595-606. doi: 10.1001/jama.2017.21421. JAMA. 2018. PMID: 29450530 Review.
Cited by
-
Prostate Specific Antigen (PSA) testing in a general practice 2009-2019.Ir J Med Sci. 2024 Oct 23. doi: 10.1007/s11845-024-03804-4. Online ahead of print. Ir J Med Sci. 2024. PMID: 39441509
-
Noninvasive multi-cancer detection using blood-based cell-free microRNAs.Sci Rep. 2024 Sep 27;14(1):22136. doi: 10.1038/s41598-024-73783-0. Sci Rep. 2024. PMID: 39333750 Free PMC article.
-
Biomarkers in Cancer Screening: Promises and Challenges in Cancer Early Detection.Hematol Oncol Clin North Am. 2024 Aug;38(4):869-888. doi: 10.1016/j.hoc.2024.04.004. Epub 2024 May 22. Hematol Oncol Clin North Am. 2024. PMID: 38782647 Review.
-
Cancer screening with multicancer detection tests: A translational science review.CA Cancer J Clin. 2024 Jul-Aug;74(4):368-382. doi: 10.3322/caac.21833. Epub 2024 Mar 22. CA Cancer J Clin. 2024. PMID: 38517462 Review.
-
Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies.J Natl Cancer Inst. 2024 Feb 8;116(2):189-193. doi: 10.1093/jnci/djad227. J Natl Cancer Inst. 2024. PMID: 37941446 Free PMC article. Review.
References
-
- Lung Cancer Alliance. Lung cancer screening and early detection. http://www.lungcanceralliance.org/facing/screening.html. Accessed Apr 24, 2008.
-
- American Urological Association. Prostate cancer screening. http://www.urologyhealth.org/adult/index.cfm?cat=05&topic=250. Accessed Apr 24, 2008.
-
- Centers for Disease Control and Prevention. Colorectal (colon) cancer. Screening guidelines. http://www.cdc.gov/cancer/colorectal/basic_info/screening/guidelines.htm. Accessed Apr 24, 2008.
-
- Armstrong JT, Brandt K, Read Y. Women’s Health Screening in Napa Valley: Uterine, Tube, and Ovarian Screening. http://www.womenshealthscreening.com/pelvic.htm. Accessed Apr 24, 2008.
-
- American Cancer Society. American Cancer Society guidelines for the early detection of cancer. http://www.cancer.org/doc-root/PED/content/PED_2_3X_ACS_Cancer_Detection.... Accessed Apr 24, 2008.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous